Stockpolly
Search
INMB · NASDAQ · Biotechnology

INmune Bio (INMB)

Develops innate-immunity therapies for rare disease, Alzheimer’s disease and cancer.

$2.43
Pre-market+0.07 (+2.97%)
At close$2.36(+5.36%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue000000000000
Gross profit000000000000
98111012910257561
Research & development6697107865241
322322223322
Selling & marketing000000000000
General & administrative322322223322
Other expenses000000017000−2
Operating income−9−8−11−10−12−9−10−25−7−5−6−1
000000001000
Interest income000000000000
Other non-operating income0000000−17−1000
Income before tax−9−8−11−10−12−9−10−24−6−5−5−1
Net income from continuing operations−9−8−11−10−12−9−10−24−6−5−5−1
Net income−9−8−11−10−12−9−10−24−6−5−5−1
EPS, basic−$0.48−$0.47−$0.61−$0.50−$0.60−$0.41−$0.43−$1.05−$0.24−$0.20−$0.20−$0.05
EPS, diluted−$0.48−$0.47−$0.61−$0.50−$0.60−$0.41−$0.43−$1.05−$0.24−$0.20−$0.20−$0.05
Weighted average shares, basic181818192022222327272727
Weighted average shares, diluted181818192022222327272727
EBITDA0−8−110−12−9−10−8−6−5−5−1
Depreciation & amortization9001000000000
EBIT−9−8−11−10−12−9−10−8−6−5−5−1